Novo Nordisk A/S (NVO): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Novo Nordisk A/S ( NVO) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.6%. By the end of trading, Novo Nordisk A/S fell $1.30 (-2.9%) to $44.09 on average volume. Throughout the day, 1,449,297 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1,624,300 shares. The stock ranged in price between $43.58-$44.70 after having opened the day at $44.69 as compared to the previous trading day's close of $45.39. Other companies within the Health Care sector that declined today were: IsoRay ( ISR), down 12.0%, Masimo ( MASI), down 10.5%, Kips Bay Medical ( KIPS), down 9.8% and Natural Alternatives International ( NAII), down 9.1%.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $124.4 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 22.8% year to date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Merrimack Pharmaceuticals ( MACK), up 59.2%, Pacific Biosciences of California ( PACB), up 17.0%, CytRx ( CYTR), up 15.6% and Biocept ( BIOC), up 13.9% , were all gainers within the health care sector with Allergan ( AGN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2